🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the fight against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting more than 82 million infections annually. Particularly high rates are reported in the African continent and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The WHO has listed it as a "critical concern". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Approval

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts anticipate that targeted use of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This approval marks a significant shift in the management of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Global Access

According to data released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which combines a dual-drug approach. The research enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to license and sell the drug in numerous regions with limited resources.

Doctors directly involved have voiced optimism. Access to a one-pill regimen of this kind is hailed as a "critical tool" for managing the epidemic. This is viewed as essential to reduce the burden of the illness for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.